Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia

Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia — Drugs · CancerIndex

Regulatory

Approvals by jurisdiction

19 approval records across 2 jurisdictions, including tumor-agnostic approvals.

emaRegulatory4 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Entrectinib	EU EMA	Tumor-agnosticLung Non-Small Cell Carcinoma	Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.conditional	approved	Jul 31, 2020	ema
Larotrectinib	EU EMA	Tumor-agnostic	Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.conditional	approved	Sep 19, 2019	ema
Repotrectinib	EU EMA	Tumor-agnosticLung Non-Small Cell Carcinoma	Augtyro as monotherapy is indicated for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). Augtyro as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with advanced solid tumours expressing a NTRK gene fusion, and who have received a prior NTRK inhibitor, or  have not received a prior NTRK inhibitor and treatment options not targeting NTRK provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1)

Data updated 19 hours agoSource updated unknown

Curated evidence

Therapies appearing in curated evidence

Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.

Data not yet available

No therapy appears in curated evidence for this entity.

Curated Items are counted regardless of level or direction; see the evidence tab for the detail.

Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.